Scarica l'app Stockscreener
1.83
3.17%
-0.06
Dopo l'orario di chiusura:
1.89
0.06
+3.28%
Precedente Chiudi:
$1.89
Aprire:
$1.98
Volume 24 ore:
398.20K
Relative Volume:
1.13
Capitalizzazione di mercato:
$45.22M
Reddito:
-
Utile/perdita netta:
$-16.51M
Rapporto P/E:
-1.3527
EPS:
-1.3528
Flusso di cassa netto:
$-15.68M
1 W Prestazione:
-10.29%
1M Prestazione:
-16.82%
6M Prestazione:
-29.62%
1 anno Prestazione:
-33.45%
Intervallo 1D:
$1.81
$2.0317
Intervallo di 1 settimana:
$1.81
$2.25
Portata 52W:
$1.675
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Nome
Medicus Pharma Ltd
Settore
Industria
Telefono
610-540-7515
Indirizzo
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Confronta MDCX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
1.83 | 46.70M | 0 | -16.51M | -15.68M | -1.3528 |
|
LLY
Lilly Eli Co
|
1,062.19 | 919.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
214.17 | 509.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.45 | 394.69B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.19 | 254.37B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.26 | 248.95B | 63.90B | 19.05B | 13.05B | 7.5596 |
Medicus Pharma Ltd Borsa (MDCX) Ultime notizie
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - The Florida Times-Union
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC - Dermatology Times
Small cap wrap: EnWave, Medicus Pharma, Ocean Power Technologies, EDM Resources, C3 Metals… - Proactive financial news
Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study - Proactive financial news
Medicus Pharma Completes Patient Enrollment for Phase 2 BCC Treatment Study - TipRanks
Medicus Pharma completes enrollment of 90 patients for Phase 2 study - TipRanks
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Manila Times
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) - GlobeNewswire
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - Greenville Online
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 - Victorville Daily Press
Medicus Pharma’s Warrant Inducement Agreement Announced - TipRanks
Medicus Pharma Elevates President Carolyn Bonner to CFO as Clinical Pipeline Accelerates - MyChesCo
Medicus Pharma Ltd. To Present at Brookline Capital Markets - Daytona Beach News-Journal
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE - Daytona Beach News-Journal
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Asheville Citizen Times
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing - The Times Telegram
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject - Daytona Beach News-Journal
Medicus Pharma secures $5.1 million from warrant exercise agreement By Investing.com - Investing.com Nigeria
Medicus Pharma secures $5.1 million from warrant exercise agreement - Investing.com India
Medicus Pharma Shakes Up Executive Ranks as President Takes on CFO Role - MSN
How Medicus Pharma Ltd. stock reacts to oil prices2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
How Medicus Pharma Ltd. Equity Warrant stock trades during market volatilityJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Is Medicus Pharma Ltd. Equity Warrant stock attractive for retirement portfoliosTrade Risk Report & Free Long-Term Investment Growth Plans - Newser
Medicus Pharma appoints Carolyn Bonner as CFO - Pharmafile
How currency fluctuations impact Medicus Pharma Ltd. stockJuly 2025 Institutional & Momentum Based Trading Ideas - Newser
Medicus Pharma Ltd. Strengthens Leadership and Expands Clinical Trials - MSN
Medicus Pharma promotes president to chief financial officer - Pennsylvania Business Report -
Should I buy Medicus Pharma Ltd. (N460) stock before earnings seasonWeekly Risk Summary & Scalable Portfolio Growth Methods - Newser
Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch - marketscreener.com
How Medicus Pharma Ltd. (N460) stock gains from tech spendingJuly 2025 Setups & Safe Capital Allocation Plans - Newser
How big funds are accumulating Medicus Pharma Ltd. (N460) stockInsider Buying & Technical Confirmation Trade Alerts - Newser
Is Medicus Pharma Ltd. (N460) stock a fit for income portfoliosJuly 2025 Pullbacks & Expert Verified Movement Alerts - Newser
Medicus Pharma shares updates on basal cell carcinoma trials - Pharmafile
Medicus Pharma Ltd Azioni (MDCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):